Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity.
Kobayashi K, Kato T, Yamamoto I, Shimizu A, Mizutani S, Asai M, Kawamoto H, Ito S, Yoshizumi T, Hirayama M, Ozaki S, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ozaki s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3100-3. doi: 10.1016/j.bmcl.2009.04.022. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19398200
Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor.
Hostetler ED, Sanabria-Bohórquez S, Fan H, Zeng Z, Gantert L, Williams M, Miller P, O'Malley S, Kameda M, Ando M, Sato N, Ozaki S, Tokita S, Ohta H, Williams D, Sur C, Cook JJ, Burns HD, Hargreaves R. Hostetler ED, et al. Among authors: ozaki s. Neuroimage. 2011 Feb 14;54(4):2635-42. doi: 10.1016/j.neuroimage.2010.11.014. Epub 2010 Nov 13. Neuroimage. 2011. PMID: 21078401
Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.
Okamoto O, Kobayashi K, Kawamoto H, Ito S, Yoshizumi T, Yamamoto I, Hashimoto M, Shimizu A, Takahashi H, Ishii Y, Ozaki S, Ohta H. Okamoto O, et al. Among authors: ozaki s. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3282-5. doi: 10.1016/j.bmcl.2008.04.037. Epub 2008 Apr 28. Bioorg Med Chem Lett. 2008. PMID: 18448337
Identification of novel benzimidazole series of potent and selective ORL1 antagonists.
Okamoto O, Kobayashi K, Kawamoto H, Ito S, Satoh A, Kato T, Yamamoto I, Mizutani S, Hashimoto M, Shimizu A, Sakoh H, Nagatomi Y, Iwasawa Y, Takahashi H, Ishii Y, Ozaki S, Ohta H. Okamoto O, et al. Among authors: ozaki s. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3278-81. doi: 10.1016/j.bmcl.2008.04.054. Epub 2008 Apr 25. Bioorg Med Chem Lett. 2008. PMID: 18468891
A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel.
Yoshizumi T, Takahashi H, Miyazoe H, Sugimoto Y, Tsujita T, Kato T, Ito H, Kawamoto H, Hirayama M, Ichikawa D, Azuma-Kanoh T, Ozaki S, Shibata Y, Tani T, Chiba M, Ishii Y, Okuda S, Tadano K, Fukuroda T, Okamoto O, Ohta H. Yoshizumi T, et al. Among authors: ozaki s. J Med Chem. 2008 Jul 10;51(13):4021-9. doi: 10.1021/jm701590h. Epub 2008 Jun 7. J Med Chem. 2008. PMID: 18537234
2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists.
Kobayashi K, Uchiyama M, Takahashi H, Kawamoto H, Ito S, Yoshizumi T, Nakashima H, Kato T, Shimizu A, Yamamoto I, Asai M, Miyazoe H, Ohno A, Hirayama M, Ozaki S, Tani T, Ishii Y, Tanaka T, Mochidome T, Tadano K, Fukuroda T, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ozaki s. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3096-9. doi: 10.1016/j.bmcl.2009.04.023. Epub 2009 Apr 11. Bioorg Med Chem Lett. 2009. PMID: 19394217
.; Kato, T.; Yamamoto, I.; Shimizu, A.; Mizutani, S.; Asai, M.; Kawamoto, H.; Ito, S.; Yoshizumi, T.; Hirayama, M.; Ozaki, S.; Ohta, H.; Okamoto, O. ...
.; Kato, T.; Yamamoto, I.; Shimizu, A.; Mizutani, S.; Asai, M.; Kawamoto, H.; Ito, S.; Yoshizumi, T.; Hirayama, M.; Ozaki …
Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.
Kobayashi K, Uchiyama M, Ito H, Takahashi H, Yoshizumi T, Sakoh H, Nagatomi Y, Asai M, Miyazoe H, Tsujita T, Hirayama M, Ozaki S, Tani T, Ishii Y, Ohta H, Okamoto O. Kobayashi K, et al. Among authors: ozaki s. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3627-31. doi: 10.1016/j.bmcl.2009.04.116. Epub 2009 May 3. Bioorg Med Chem Lett. 2009. PMID: 19447610
Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate.
Satoh A, Sagara T, Sakoh H, Hashimoto M, Nakashima H, Kato T, Goto Y, Mizutani S, Azuma-Kanoh T, Tani T, Okuda S, Okamoto O, Ozaki S, Iwasawa Y, Ohta H, Kawamoto H. Satoh A, et al. Among authors: ozaki s. J Med Chem. 2009 Jul 23;52(14):4091-4. doi: 10.1021/jm900581g. J Med Chem. 2009. PMID: 19537798
1,126 results